{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"16.59","upperLimit":"28.52","value":"21.1"},{"comment":"Median duration OS could not be estimated for placebo at data cut-off June 15, 2011 due to insufficient number of participants with events. At time of analysis of PFS, number of deaths required to conduct primary analysis of OS was not reached.","groupId":"OG001","lowerLimit":"17.41","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"219"},{"groupId":"OG001","value":"111"}],"units":"Participants"}],"description":"Duration of Overall Survival (OS) from the time of randomization to death due to any cause. A Kaplan-Meier analysis was performed to estimate the median.","dispersionType":"95% Confidence Interval","groups":[{"description":"XL184 175 mg L-malate salt weight; 138 mg freebase equivalent weight, oral capsules once daily","id":"OG000","title":"XL184 (Cabozantinib)"},{"description":"Oral capsules once daily","id":"OG001","title":"Placebo"}],"paramType":"MEDIAN","populationDescription":"Intent to treat (ITT) randomized to either XL184 or placebo","reportingStatus":"POSTED","timeFrame":"The pre-specified interim analysis of Overall Survival (OS) was assessed at 44% of required events. Includes data up to 15June2011. As of this date, the number of deaths required to conduct the primary analysis had not been reached.","title":"Overall Survival (OS) With XL184 Compared With Placebo","type":"SECONDARY","unitOfMeasure":"months"}